MARKET

SLS

SLS

Sellas Life Sciences Group Inc
NASDAQ
1.740
+0.200
+12.99%
Pre Market: 1.810 +0.07 +4.02% 07:04 12/05 EST
OPEN
1.540
PREV CLOSE
1.540
HIGH
1.840
LOW
1.518
VOLUME
8.88K
TURNOVER
0
52 WEEK HIGH
2.480
52 WEEK LOW
0.7720
MARKET CAP
247.85M
P/E (TTM)
-6.0627
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SLS last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at SLS last week (1117-1121)?
Weekly Report · 11/24 09:33
Director Makes Bold Move with Major Stock Purchase in SELLAS Life Sciences
TipRanks · 11/22 02:08
Director Katherine Bach Kalin Acquires Common Shares of Sellas Life Sciences Group Inc
Reuters · 11/21 13:45
Alliance Global Partners Sticks to Its Buy Rating for SELLAS Life Sciences Group (SLS)
TipRanks · 11/18 08:25
Weekly Report: what happened at SLS last week (1110-1114)?
Weekly Report · 11/17 09:34
Buy Rating for SELLAS Life Sciences Group: Financial Stability and Promising Clinical Developments Drive Positive Outlook
TipRanks · 11/14 16:15
SELLAS Life Sciences GAAP EPS of -$0.06 beats by $0.02
Seeking Alpha · 11/13 05:20
More
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

Webull offers Sellas Life Sciences Group Inc stock information, including NASDAQ: SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.